RxDoctor Payments Data

Jose Valle, MD

Pulmonary Disease · Naples, FLNPI 1992936488

Payments from drug & device makers

$50,029in general payments, 2019–2025

Across 101 payments — averaging $495.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$45K
  • Inspire Medical Systems, Inc.$2K
  • Jazz Pharmaceuticals Inc.$722
  • GSK$468
  • Inari Medical, Inc.$380
  • Avadel CNS Pharmaceuticals, LLC$364
  • plus $943 from 10 others

What the payments were for

  • Consulting fees$4,7259%
  • Speaking & faculty fees$38,47577%
  • Travel & lodging$2,2945%
  • Food & beverage$4,5359%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,029 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$500,677
Medicare patients
1,228
Services billed
3,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter124$103,448
Breo ElliptaFluticasone/Vilanterol103$62,114
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr90$50,449
SymbicortBudesonide/Formoterol Fumarate25$9,620
Arnuity ElliptaFluticasone Furoate17$4,024
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,265
Albuterol Sulfate HfaAlbuterol Sulfate54$1,551
Fluticasone Propionate90$1,525
Azelastine Hcl37$1,085
Modafinil12$720
Montelukast Sodium43$482
Ropinirole Hcl31$373
Prednisone29$191
Zolpidem Tartrate42$191
Azithromycin11$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$468$220,034334 claims
AstraZenecaSymbicort$17$9,62025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →